For the month ended 31 October 2025, Kintor Pharmaceutical Limited (09939) reported that its authorized share capital remained at 700,000,000 ordinary shares at a par value of US$0.0001 per share, totaling US$70,000. This reflects no change compared to the close of the preceding month.

The company’s issued share capital also remained unchanged at 468,172,600 ordinary shares with zero treasury shares. The latest report indicates no additional issuance of options, warrants, or other convertible securities, and no activities involving other agreements or arrangements to issue shares. The company confirms compliance with relevant listing and regulatory requirements throughout the reporting period.